Skip to main content
Find more clinical trials

Longitudinal Innate Immunity and Aging Study (LIIA)

Start: April 30, 2019
End: March 31, 2024
Enrollment: 300

What Is This Study About?

This observational study plans to examine the biological bases of cognitive aging. The goals of the study are to better understand how immune system markers, in the blood and in cerebrospinal fluid, are related to aging over time. Over a two-year period, participants will undergo a series of tests and assessments that will measure immune markers in blood and cerebrospinal fluid and changes in cognitive function. They will also examine changes in brain structure and levels of proteins associated with Alzheimer's disease. This research may help scientists better understand what puts individuals at risk for cognitive decline and Alzheimer's disease.

Do I Qualify To Participate in This Study?

Minimum Age: 60 Years

Maximum Age: 89 Years

Must have:

  • Study partner with contact at least twice per month who can provide information about functional abilities
  • Adjusted Mini-Mental State Examination score greater than 23
  • Clinical Dementia Rating global score of 0
  • No significant cognitive decline in last year
  • No evidence of a neurodegenerative disorder

Must NOT have:

  • Major psychiatric disorder, such as schizophrenia, bipolar disorder, or untreated major depression in past year
  • Neurological conditions affecting cognition, including Parkinson's disease, epilepsy (onset prior than two years ago), head trauma with loss of consciousness longer than five minutes in the past two years, large vessel infarct, mild cognitive impairment, or dementia
  • Central nervous system (CNS) immune conditions and other conditions affecting cognition, such as multiple sclerosis, paraneoplastic encephalitides, Hashimoto's encephalopathy, and systematic lupus erythematosus
  • Systematic illness, such as current cancer, kidney failure, or respiratory failure
  • Substance abuse/dependence
  • Prohibited medications: drugs likely to affect the CNS (e.g., long-acting benzodiazepines, neuroleptics in the phenothiazine and haloperidol families); anticoagulants, antiplatelets, heparin shots, or other blood thinner medications (e.g., warfarin, dabigatran, rivaroxaban, apixaban, clopidogrel)
  • Significant hearing, visual, or motor deficits that would interfere with cognitive testing
  • Factors that preclude magnetic resonance imaging (e.g., pacemaker or metal implants)
  • Factors that preclude lumbar puncture (e.g., lower back surgery)

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 
Study Contact
Neurology Research Partners
Michelle Stocker

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Colorado
University of Colorado Anschutz Medical Campus
Aurora, CO 80045
Recruiting
Michelle Stocker

Who Sponsors This Study?

Lead: University of Colorado, Denver

Collaborator Sponsor

  • National Institute on Aging (NIA)

Source: ClinicalTrials.gov ID: NCT03944603